Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 50Lymphoma 30Lung Neoplasms 29Breast Neoplasms 28Prostatic Neoplasms 26Multiple Myeloma 25Melanoma 22Lymphoma, Non-Hodgkin 20Carcinoma, Non-Small-Cell Lung 20Ovarian Neoplasms 19Leukemia, Myeloid, Acute 19Neoplasm Metastasis 18Glioma 18Pancreatic Neoplasms 17Colorectal Neoplasms 16Urinary Bladder Neoplasms 15Hematologic Neoplasms 15Carcinoma, Renal Cell 15Sarcoma 14Burkitt Lymphoma 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Neuroblastoma 13Colonic Neoplasms 12Carcinoma 12Thyroid Neoplasms 11Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Myelodysplastic Syndromes 11Leukemia, Lymphocytic, Chronic, B-Cell 11Ependymoma 11

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pathologic Processes × 30 days × Clear all
NCT05797246 2026-05-29

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
21 enrolled

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡